SymBio Pharmaceuticals Limited [4582.T]
TOKYO, Mar 30 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582.T) extended its three-year cooperative research agreement (CRADA) with the US National Institutes of Health's National Institute of Neurological Disorders and Stroke (NIH/NINDS) for multiple sclerosis treatment development. The extension supports further clinical trials for BCV, which showed high antiviral activity against Epstein-Barr Virus (EBV) in preclinical studies.
"We are advancing our joint research with NIH/NINDS towards clinical trials," said Fumiki Yoshida, President and CEO of SymBio Pharmaceuticals. "We also initiated clinical trials for Progressive Multifocal Leukoencephalopathy (PML) under another CRADA with NIH/NINDS." Results from previous research, published in the prestigious Journal of Clinical Investigation in January 2026, confirmed BCV’s strong inhibitory effect on reactivated EBV.
The updated CRADA extends until March 2029, aiming to validate BCV's efficacy through human clinical trials while developing suitable delivery methods for chronic disease treatments. This extension does not impact SymBio Pharmaceuticals' fiscal year ending December 2026.
🟡 Confidence: Standard AI-translated content.